biostudies-literatureCorey KENCATS NIH HHSNIDDK NIH HHSNational Institutes of HealthNIH HHS1205-1213https://www.ebi.ac.uk/biostudies/studies/S-EPMC6461513biostudies-literatureUnknown49(9)<h4>Background</h4>Dyslipidaemia is frequent in non-alcoholic steatohepatitis (NASH); however, it is unclear if improvement in liver histology is associated with favourable changes in cardiovascular disease (CVD) risk.<h4>Aims</h4>To evaluate the relationship of NASH resolution and lipoprotein subfraction levels, markers of endothelial dysfunction, and macrophage activation.<h4>Methods</h4>One hundred and seventeen individuals with NASH who participated in the Pioglitazone vs Vitamin E vs Placebo for the Treatment of Nondiabetic Patients with NASH (PIVENS) trial with paired liver biopsies and serum samples available at baseline and after 96 weeks of treatment were included. Participants in the PIVENS trials received vitamin E, pioglitazone, or placebo for 96 weeks. Lipoprotein subfraction Alimentary pharmacology & therapeuticsRelationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial.PMC6461513K23 DK099422U24 DK061730K23DK099422DK078772K24 DK078772UL1 TR002548U01 DK061732U01 DK061713U01 DK061730Clark JClark LTonascia JMerriman RChalasani NAbrams SHSiegner JFairly LAWilson LLavine JEVuppalanchi RKwan SLiu YCArceo DBryan DKowdley KVChung RTBrunt EMSirlin CMurray KFHawkins CPabst MSubbarao GMiriel LStager MNeuschwander-Tetri BASchwimmer JBSandhu BHoffmann JKillenberg PPiercy DPatton HYoung MByam EWhite MAbdelmalek MDerdoy JStein TLee LSteel TMooney JMann PJones ABoyett SScheimann AOSanyal AJKrauss RMFilipowski DSargeant CParman ZTorbenson MStewart SKleiner DEBhimalli PBringman DYates KPGreen MKim WBehling CMcCullough ANASH Clinical Research NetworkNatta MVDonithan MSternberg AYates KMendoza SThompson JBarlow SLydecker AGuy CSaunders CMohan PColvin RIsaacson MSargent RPan YPNelson JHuang TTHoofnagle JGottfried MLuketic VACFerrell LDDurelle JCoffey MCorey KERobuck PRBrancati FWilson LAEspinosa DHollick RDoo EAltinbas AFeldstein ANair KBambha KKlipsch AMolleston JPCummings OWRosenthal PDasarathy SRagozzino LRosenthal MUnalp-Arida ADiehl AMBass NMPfeifer KKing DSmith MFuchs MBelt PContos MJYeh MfalseRelationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial.<h4>Background</h4>Dyslipidaemia is frequent in non-alcoholic steatohepatitis (NASH); however, it is unclear if improvement in liver histology is associated with favourable changes in cardiovascular disease (CVD) risk.<h4>Aims</h4>To evaluate the relationship of NASH resolution and lipoprotein subfraction levels, markers of endothelial dysfunction, and macrophage activation.<h4>Methods</h4>One hundred and seventeen individuals with NASH who participated in the Pioglitazone vs Vitamin E vs Placebo for the Treatment of Nondiabetic Patients with NASH (PIVENS) trial with paired liver biopsies and serum samples available at baseline and after 96 weeks of treatment were included. Participants in the PIVENS trials received vitamin E, pioglitazone, or placebo for 96 weeks. Lipoprotein subfraction 2019-01-01T00:00:00Z2019 May2026-05-03T12:00:53.652Z2020-05-22T18:47:32ZS-EPMC64615133085469410.1111/apt.15216